Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074455 | 0.99 | ENPP2 (0.39) | ENPP2LPAR1LPAR3CTSSHDAC1 | |
| SCHEMBL10074987 | 0.99 | ENPP2 (0.39) | ENPP2LPAR1LPAR3CTSSHDAC1 | |
| SCHEMBL10074135 | 0.95 | CTSS (0.35) | CTSSPSMB5CTSD | |
| SCHEMBL10077372 | 0.93 | ENPP2 (0.38) | ENPP2LPAR1LPAR3HDAC1HDAC6 | |
| SCHEMBL10075000 | 0.92 | LPAR1 (0.36) | ENPP2LPAR1LPAR3CTSSHDAC1 | |
| SCHEMBL12291363 | 0.92 | ENPP2 (0.41) | ENPP2LPAR1LPAR3HDAC1HDAC6 | |
| SCHEMBL6874881 | 0.91 | ENPP2 (0.42) | ENPP2LPAR1LPAR3HDAC1HDAC6 | |
| SCHEMBL6875612 | 0.91 | ENPP2 (0.42) | ENPP2LPAR1LPAR3HDAC1HDAC6 | |
| SCHEMBL10078261 | 0.88 | PSMB11 (0.38) | CTSSPSMB5CTSD | |
| SCHEMBL10078263 | 0.88 | CTSS (0.35) | CTSSPSMB5CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418196-A1 | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors | IMTM GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | ENPP2 134/4885LPAR1 2015/4885LPAR3 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.